Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Published:2015-04-09 Issue:7 Volume:75 Page:777-796
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Keating Gillian M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-015-0385-y.pdf

Reference85 articles.

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.

2. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–58.

3. Capuano A, Sportiello L, Maiorino MI, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy: focus on alogliptin. Drug Des Dev Ther. 2013;7:989–1001.

4. Takeda Pharmaceuticals America Inc. Nesina (alogliptin) tablets: US prescribing information. 2013. http://www.takeda.us/products/default.aspx . Accessed 3 Mar 2015.

5. European Medicines Agency. Vipidia (alogliptin): EU summary of product characteristics. 2014. http://www.ema.europa.eu/ . Accessed 3 Mar 2015.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Collaboration of alogliptin and pioglitazone: a double hit on the target;Meditsinskiy sovet = Medical Council;2024-05-18

2. Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies;Molecules;2024-05-14

3. Retagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial;Diabetes, Obesity and Metabolism;2024-04-11

4. Understanding the Pharmacological and Nanotechnological Facets of Dipeptidyl Peptidase-4 Inhibitors in Type II Diabetes Mellitus: a Paradigm in Therapeutics;BioNanoScience;2023-11-18

5. GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy;Biomedicines;2023-11-12